Signaling Pathway News and Research

RSS

OncoMed, Bayer Schering Pharma to develop and commercialize novel anti-cancer stem cell therapeutics

OncoMed Pharmaceuticals, Inc. and Bayer Schering Pharma AG, Germany, today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway. Cancer stem cells are a subset of tumor cells believed to play a significant role in the establishment, metastasis and recurrence of cancer.

17 Jun 2010

Identification of key player in signaling pathway offers hope for new targeted melanoma therapies

Identification of a key player in a signaling pathway involved in the development of melanoma - the deadliest form of skin cancer - may offer hope for new targeted melanoma therapies.

16 Jun 2010

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today presented preclinical and clinical data on CAL-101, the Company's oral, delta selective PI3K inhibitor at the 15th Congress of the European Hematology Association in Barcelona, Spain.

14 Jun 2010

Researchers differentiate human stem cells to become heart cells with cardiomyopathy

Researchers at Mount Sinai School of Medicine have for the first time differentiated human stem cells to become heart cells with cardiomyopathy, a condition in which the heart muscle cells are abnormal. The discovery will allow scientists to learn how those heart cells become diseased and from there, they can begin developing drug therapies to stop the disease from occurring or progressing. The study is published in the June 9th issue of Nature.

10 Jun 2010

Scientists discover how polyphenols present in red wine and green tea inhibit prostate cancer growth

In what could lead to a major advance in the treatment of prostate cancer, scientists now know exactly why polyphenols in red wine and green tea inhibit cancer growth. This new discovery, published online in The FASEB Journal, explains how antioxidants in red wine and green tea produce a combined effect to disrupt an important cell signaling pathway necessary for prostate cancer growth.

10 Jun 2010

Harvard and University of Montreal researchers challenge views on how cells respond to stimuli

People have them, cats have them and whales have some, too. Neurons, those interlinked nerve cells that carry sensations including pain, stretch from our spinal cords to the tips of our toes, paws or fins. According to a new study published in the journal Cell, scientists from the Harvard Medical School, the University of Montreal and the Dana-Farber Cancer Institute have found a new way by which nerve cells relay information that tell them to grow from millimeters to meters in length.

9 Jun 2010

Preclinical data of dual TLR7 and TLR8 agonist in cancer published

Idera Pharmaceuticals, Inc. today announced the publication of data from studies of a dual agonist of Toll-like Receptor 7 and TLR8 in preclinical models of cancer. The Company created this first-in-class RNA-based dual agonist of TLR7 and TLR8 through its chemistry-based approach to identifying novel TLR-targeted drug candidates.

4 Jun 2010

Asuragen obtains license to integrate BRAF V600E mutation sequence into its molecular diagnostic products

Asuragen, Inc., a leader in molecular diagnostics and RNA-based pharmacogenomics services, announced today that it has obtained a non-exclusive license to incorporate the BRAF V600E mutation sequence into Asuragen's molecular diagnostic products. The license was obtained from Johns Hopkins University and includes the use of the BRAF V600E mutation as a component of diagnostic test kits and for use in Asuragen's CLIA laboratory for clinical research and patient testing.

2 Jun 2010

Study sheds light on molecular mechanisms of genital and urinary tract abnormalities

Scientists have learned how a gene widely known for precisely positioning and sculpting various organs also controls the speed of cell division, a finding that could be useful for understanding the explosive growth of cancer cells or why increasing numbers of children are being born with genital and urinary tract malformations.

2 Jun 2010

Scientists study interaction between Notch signaling pathway and BCL6 gene to understand how cancer forms

A Florida State University College of Medicine researcher has discovered a new interaction between a cell signaling system and a specific gene that may be the cause of B-cell lymphoma. The finding suggests a similar interaction could be occurring during the development of other types of cancer, leading to further understanding of how cancer works — and how it might be stopped.

28 May 2010

NIDDK awards Albert Einstein College of Medicine $9.5M for continuation of Diabetes Research and Training Center

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has awarded Albert Einstein College of Medicine of Yeshiva University a five-year, $9.5 million grant for the continuation of its Diabetes Research and Training Center (DRTC). The DRTC was also awarded a $632,000 supplemental grant for equipment and additional pilot and feasibility studies through the American Recovery and Reinvestment Act (ARRA), bringing total NIH support to $10,177,000.

26 May 2010

Folate supplementation thwarts heart birth defects induced by alcohol exposure in early pregnancy

A new animal study has found that high levels of the B-vitamin folate (folic acid) prevented heart birth defects induced by alcohol exposure in early pregnancy, a condition known as fetal alcohol syndrome.

25 May 2010

Female sex hormones may work with estrogen in reducing airway constriction: Research

Female sex hormones may work with beta-agonists in reducing airway constriction, according to new bench research from the Mayo Clinic.

17 May 2010

Mutations in STRAD-alpha gene can cause PMSE syndrome in Amish children: Penn researchers

So often the rare informs the common. Penn researchers investigating a regulatory protein involved in a rare genetic disease have shown that it may be related to epileptic and autistic symptoms in other more common neurological disorders.

12 May 2010

Angiogenesis inhibitors safe for cancer patients despite hypertension risk: Panel

A new class of cancer drugs can be used effectively while minimizing hypertensive side effects if patients' blood pressure is closely monitored and controlled, a clinical panel has determined.

12 May 2010

Progenics Pharmaceuticals reports net loss of $18.6M in first-quarter 2010

Progenics Pharmaceuticals, Inc. today announced its results of operations for the quarter ended March 31, 2010.

11 May 2010

Mothers with preeclampsia at reduced risk of developing breast cancer

Preeclampsia is a high blood pressure syndrome in pregnant mothers that is caused when the blood supply in the placenta of the developing baby is restricted. The blood-deprived placenta releases factors that cause the raise in blood pressure in the mother. Doctors have to monitor these women closely and they may be forced to deliver the baby early to protect the mother and the baby. Most women's blood pressure returns to normal levels after they deliver the placenta.

26 Apr 2010

NO-naproxen blocks molecular changes leading to colorectal cancer development

Past randomized clinical trials have shown that non-steroidal anti-inflammatory drugs (NSAIDs), including naproxen, can reduce the risk of colon cancer and precancerous polyps in humans. Now, researchers at Fox Chase Cancer Center have found that an investigational form of naproxen, called nitric oxide-donating naproxen (NO-naproxen), can block one of the earliest molecular changes that lead to colorectal cancer development while also reducing gastrointestinal toxicity, a relatively common side effect associated with NSAIDs.

22 Apr 2010

New treatment modalities for RCC

Renal cell carcinoma accounts for about 3% of all solid tumours in adults, and worldwide, more than 200.000 new cases and 100.000 deaths result each year from this malignancy.

21 Apr 2010

Surgery still the only measure to cure RCC

Renal cell carcinoma (RCC) accounts for about 3% of all solid tumours in adults, and worldwide, more than 200.000 new cases and 100.000 deaths result each year from this malignancy.

19 Apr 2010